In this study, we aimed to assess early tumor response using different radiological criteria (RECIST 1.1, mRECIST, Choi, and rChoi) and to correlate the evaluation categories with the OS of patients with uHCC treated with an anti-PD-1 antibody plus bevacizumab. The gene discussed is PDCD1; the disease is neoplasm.